Susan Merenstein, Pharmacist/Owner

(412) 586-4678

Back

Bone Strength vs Bone Density: Rethinking Osteoporosis, Calcium, and Fracture Risk (A bone-strength–focused framework for men and women)

January 6, 2026

Bone Strength vs Bone Density: Rethinking Osteoporosis, Calcium, and Fracture Risk

(A bone-strength–focused framework for men and women)

Introduction

Osteoporosis has long been framed as a disease of calcium deficiency and treated primarily by attempting to raise bone mineral density (BMD) on a DEXA scan. Yet fractures—the outcome that truly matters—often occur in individuals with “osteopenia” or even “normal” bone density, while others with low T-scores remain fracture-free.

This disconnect highlights a fundamental issue: bone density is not the same as bone strength.

Bone strength reflects not only mineral content, but also bone microarchitecture, collagen matrix integrity, hormonal signaling, muscle mass, balance, and mechanical loading. This framework applies equally to men and women. The biological processes governing bone remodeling are the same; the difference lies primarily in which hormones decline and require attention.

There are 2 types of bone cells important in the process of osteoporosis: osteoclasts (bone resorption)and osteoblasts (bone formation). Osteoporosis in women typically starts in the mid-thirties, often 15 years before menopause, with a bone loss of 1-1.5% per year.

This document outlines a bone-strength–focused approach to secondary osteoporosis, written for both clinicians and informed patients.

Bone Strength vs Bone Density

DEXA scanning measures bone mineral density but does not assess:

  • Bone microarchitecture
  • Collagen matrix quality
  • Cortical thickness
  • Trabecular connectivity
  • Muscle mass or neuromuscular function
  • Fall risk

Fracture risk is determined by bone strength, which reflects density and quality, along with mechanical loading and muscle support. Individuals with similar T-scores may have markedly different fracture risks.

Low Bone Density Does Not Necessarily Mean Fragile Bone

Bone mineral density (BMD) reflects the quantity of mineral in bone, not bone quality. BMD does not assess bone strength, microarchitecture, turnover, geometry, or collagen integrity — all of which contribute to fracture risk.

This explains why individuals with similar DEXA scores may have vastly different fracture outcomes.

The Calcium–Bone Paradox

High dairy intake or high-dose calcium supplementation has not been shown to meaningfully reduce fracture risk in adults. Calcium functions as a substrate, not a signaling agent. Without adequate magnesium, vitamin D, vitamin K2, hormonal signaling, and mechanical loading, calcium does not improve bone quality and may be misdirected to soft tissues, including vascular tissue.

Clinical focus should therefore shift away from calcium-centric strategies and toward bone remodeling signals, collagen integrity, muscle preservation, and fracture prevention.

Foundational Bone-Strength Strategy (Men and Women)

Key Micronutrients & Functional Dosing Guidance

Doses are individualized and guided by body weight, laboratory assessment, and clinical context.

  • Oral Magnesium Capsules or well-absorbed powder
    Essential for parathyroid hormone signaling, vitamin D activation, calcium utilization, and bone crystal formation.
    Dose framework: ~5 mg per pound of body weight per day
    (commonly divided doses; well-absorbed forms preferred)
  • Vitamin D3
    Permissive for mineral absorption, bone turnover regulation, muscle strength, and fall prevention.
    Dose framework: ~45–50 IU per pound of body weight per day
    Target serum 25-OH vitamin D: ~50–70 ng/mL
  • Vitamin K2 (MK-7)
    Activates osteocalcin and directs calcium into bone and away from soft tissues.
  • Vitamin C
    Required for collagen synthesis and bone matrix tensile strength.
  • B-Vitamins (B6, B12, Folate)
    Support homocysteine metabolism; elevated homocysteine is associated with increased fracture risk.
  • Zinc & Boron
    Support osteoblast activity, collagen synthesis, and mineral metabolism.
  • Strontium (non-pharmaceutical forms)
    May support bone material properties; DEXA interpretation requires caution due to atomic-weight effects.

Omega-3 Fatty Acids & Bone Health

Omega-3 fatty acids (EPA and DHA) affect bone primarily through inflammation control and signaling balance, not by adding mineral. This matters because chronic low-grade inflammation accelerates bone loss, especially post-menopause and with aging. Higher omega-3 intake → slower bone loss and lower hip fracture risk.

Key mechanisms:

  • ↓ Pro-inflammatory cytokines (IL-6, TNF-α) that stimulate osteoclasts
  • ↑ Osteoblast differentiation and activity
  • ↓ Osteoclastogenesis (bone resorption)
  • Improved muscle function → ↓ fall risk

The Gut Microbiome & Bone Health

Omega 3’s favorably shift the gut microbiome.

The gut microbiome influences bone via three major pathways:

1. Mineral absorption

  • Magnesium and calcium absorption are microbiome-dependent
  • Dysbiosis → reduced mineral bioavailability even with adequate intake

2. Immune signaling

  • Gut bacteria regulate systemic inflammation
  • Dysbiosis → ↑ IL-6, TNF-α → ↑ osteoclast activity
  • A balanced microbiome promotes a bone-protective immune profile

3. Hormone metabolism

  • The microbiome participates in estrogen recycling (estrobolome)
  • Dysbiosis may worsen postmenopausal bone loss by altering estrogen availability
  • Cortisol metabolism is also affected

Patients with:

  • IBS, IBD, celiac disease
  • Long-term PPI use
  • Recurrent antibiotics
  • Chronic stress

often have bone loss that does not respond to calcium or DEXA-driven strategies alone.

Collagen & Bone Matrix Support

Bone is approximately 30–40% collagen by volume. Collagen provides flexibility and resistance to microfracture—properties not captured by DEXA scanning.

  • Bone broth provides collagen, glycine, proline, and trace minerals.
  • Whole-body collagen powder (typically 10–20 g/day) supports bone and connective tissue integrity, particularly when paired with adequate vitamin C.

Mechanical Loading & Lifestyle

Mechanical loading is the primary osteogenic stimulus:

  • Progressive resistance training improves cortical thickness and femoral neck geometry
  • Impact and weight-bearing exercise stimulate adaptive bone remodeling
  • Walking alone is insufficient to strengthen the hip and femoral neck
  • Addressing sarcopenia is essential for fracture prevention in both sexes

Hormonal Regulation of Bone Strength

Bone remodeling is hormonally regulated in both men and women. The underlying pathways are the same; differences arise from which hormones decline with age.

Bone remodeling is governed by a dynamic balance between osteoclasts (bone resorption) and osteoblasts (bone formation). Osteoporosis develops when bone resorption chronically exceeds bone formation, leading to loss of bone mass and deterioration of bone quality over time.

Estrogen

In women, bone loss accelerates during the menopausal transition, especially in the first 2 post menopausal years as estrogen production declines by 40-60%. Estrogen deficiency increases the activity of osteoclasts in part through inflammatory signaling pathways, including increased interleukin-6 (IL-6), resulting in heightened bone resorption. This effect is most pronounced during the first 5 postmenopausal years. After this period, the body adjusts to lower estrogen levels.

While estrogen therapy may temporarily slow bone loss, it does not reliably restore bone structure or reverse established osteoporosis when used alone. Additionally, estrogen-only strategies do not address bone formation and must be considered in the context of individual risk of endometrial cancer, and a slightly increases risk of breast and cervical cancer.

Progesterone

Progesterone plays a direct and essential role in bone formation. At menopause, and even in a woman’s 30’s progesterone production falls sharply, leading to reduced osteoblast activity and impaired new bone formation.

Bone loss in postmenopausal women reflects not only estrogen deficiency, but also a loss of progesterone-driven bone building. Clinical evidence supports progesterone as a necessary factor in maintaining bone mass and supporting bone density when adequate nutrition, mechanical loading, and hormonal balance are present. Natural Human Identical Progesterone hormone is an essential factor in the prevention and proper treatment of Osteoporosis.

*Hormonal Balance Matters

When progesterone becomes deficient and estrogen remains relatively dominant, estrogen may exert adverse effects rather than protective ones. Balanced hormone signaling — not hormone replacement in isolation — is essential for maintaining healthy bone remodeling.

Testosterone (Women and Men)

Testosterone contributes to bone strength by supporting the formation and retention of calcium hydroxyapatite within the bone matrix, preserving cortical thickness and enhancing overall bone integrity.

In women, relative testosterone deficiency — common after menopause — contributes to reduced bone strength, impaired mineralization, and loss of muscle mass. Estrogen may slow bone loss and progesterone may stimulate bone formation, but without adequate testosterone and mineral support, bone remains structurally weak.

Although testosterone is not FDA-approved specifically for the treatment of osteoporosis, clinical studies demonstrate a clear association between testosterone levels and bone density in both women and men.

Hormones Relevant to Bone Strength in Both Sexes

  • Testosterone: supports osteoblast activity, cortical bone thickness, muscle mass, and fall prevention
  • DHEA: upstream precursor supporting androgen and estrogen availability
  • Cortisol: chronic elevation accelerates bone loss and muscle wasting

Additional Hormonal Emphasis in Women

  • Progesterone: directly stimulates bone formation via osteoblastic activity
  • Estradiol: reduces bone resorption; timing and delivery matter.

Loss of progesterone and androgens in women helps explain why estrogen-only strategies often fail to prevent fractures.

Key point:

The supplementation strategy does not change by sex.

What changes is which hormones must be evaluated and optimized.

Adjunctive Consideration: CBD

Emerging evidence suggests cannabidiol (CBD) may influence bone remodeling and fracture healing via modulation of osteoblast and osteoclast activity and inflammatory signaling. Clinical use remains adjunctive and individualized.

Clinical Summary

Osteoporosis—particularly secondary osteoporosis—reflects the interaction of hormonal decline, collagen loss, sarcopenia, micronutrient imbalance, medication effects, and inadequate mechanical loading. A bone-strength–focused approach addresses fracture risk beyond bone density alone and applies to both men and women, with hormone-specific nuance.

Addendum:

Advanced Bone Assessment & Turnover Monitoring

(Beyond DEXA: Bone Quality, Remodeling Activity, and Fracture Risk)

Bone Density vs Bone Quality

Standard DEXA scanning measures bone mineral density (BMD) but does not fully assess bone quality, including microarchitecture and structural integrity. This limitation explains why fracture risk may be underestimated in some individuals and overestimated in others.

Trabecular Bone Score (TBS)

An add-on to DEXA, Trabecular Bone Score (TBS) evaluates the texture of trabecular bone and provides indirect information about bone microarchitecture.

  • Enhances fracture risk prediction independent of BMD
  • Helps differentiate low-density but structurally sound bone from fragile bone
  • Particularly useful in postmenopausal women and patients with secondary osteoporosis

TBS improves clinical decision-making by assessing bone quality, not just quantity.

REMS Scan (Radiofrequency Echographic Multispectrometry)

REMS, performed using the Echolight device, is a radiation-free ultrasound-based technology that evaluates both bone density and bone quality.

Key features:

  • Measures bone density and microarchitecture
  • Provides a 5-year fragility fracture risk score
  • Useful when DEXA results are inconclusive or discordant with clinical risk
  • Particularly valuable for serial monitoring

REMS offers a promising adjunctive tool for assessing true skeletal strength.

Bone Turnover: Why Activity Matters

Bone is not static. The skeleton is continuously remodeled, with complete renewal occurring approximately every 7–10 years. Fracture risk depends not only on bone density and quality, but also on bone turnover rate — the balance between bone breakdown and bone formation.

Excessive turnover accelerates bone loss. Suppressed turnover may increase bone brittleness.

Key Bone Turnover Markers (Measured Together)

To assess remodeling activity accurately, two markers must be interpreted together:

  • CTX (C-terminal telopeptide) – marker of bone resorption
    Optimal reference range: ~250–500 pg/mL
  • P1NP (Procollagen Type 1 N-Terminal Propeptide) – marker of bone formation
    Optimal reference range: ~30–60 ng/mL

These markers are available together through Osteo IQ panels (LabCorp or Quest).

The ratio of CTX to P1NP provides insight into whether bone is predominantly breaking down, building up, or balanced, and helps guide therapeutic decisions.

Anabolic v Antiresorptive Thereapy: Clinical Context

In patients with severely compromised bone quality, multiple fragility fractures, or very high fracture risk, anabolic therapies may be considered.

Anabolic (Bone-Building) Agents

  • Teriparatide (Forteo)
  • Abaloparatide (Tymlos)
  • Romosozumab (Evenity)

These agents stimulate osteoblast activity and can rapidly improve bone quality and structure, particularly in high-risk patients.

Sequential Therapy Requirement

Anabolic therapy must be followed by antiresorptive therapy to maintain gains. Without this transition, newly formed bone may be lost.

Common follow-up agents include:

  • Alendronate (Fosamax)
  • Risedronate (Actonel)
  • Zoledronic acid (Reclast)
  • Ibandronate (Boniva)

However:

  • Long-term antiresorptive use (>5 years) is associated with over-suppression of bone remodeling
  • Suppressed remodeling may produce harder but more brittle bone, lacking flexibility and resilience

For this reason, functional and integrative models emphasize time-limited, strategic use, not indefinite therapy.

Key Clinical Takeaways

  • Bone strength depends on density, quality, and turnover
  • DEXA alone is insufficient for comprehensive fracture risk assessment
  • TBS and REMS provide insight into bone microarchitecture and quality
  • CTX and P1NP together reveal current and future remodeling behavior
  • Anabolic therapy may be appropriate for select high-risk patients but requires thoughtful sequencing and duration

The goal is not simply denser bone, but resilient, flexible bone capable of adapting to mechanical stress.

Addendum Practical Support and Nutrition:

https://vitalhealthpharmacist.com/blog/2026/01/addendum-practical-support-nutrition/

Addendum Comprehensive Bone Health FAQ:

https://vitalhealthpharmacist.com/blog/2026/01/addendum-comprehensive-bone-health-faq/

This content is intended for educational and informational purposes only and should not be construed as medical advice. The information presented reflects current evidence and clinical perspectives but does not substitute for individualized medical care. Readers should consult their physician or qualified healthcare provider before making changes to medications, supplements, exercise programs, or treatment plans.

References:

Bone Strength vs Bone Density

Seeman E, Delmas PD. Bone quality—the material and structural basis of bone strength. New England Journal of Medicine. 2006;354:2250–2261.

Siris ES et al. Bone mineral density thresholds for fracture risk. Archives of Internal Medicine. 2004;164:1108–1112.

Calcium Intake, Fracture Risk & the “Calcium Paradox”

Bolland MJ et al. Calcium intake and fracture prevention: systematic review. BMJ. 2015;351:h4580.

Reid IR et al. Effects of calcium supplementation on fracture risk. Lancet. 2014;383:146–155.

Tai V et al. Calcium intake and bone mineral density. BMJ. 2015;351:h4183.

Cardiovascular Disease & Calcium Supplementation

Levy T. Death by Calcium. MedFox Publishing; 2014.

Levy T. Calcium supplementation, vitamin K deficiency, and vascular calcification. Journal of Orthomolecular Medicine.

Levy T. Coronary artery calcification and misplaced calcium. Medical Hypotheses.

Testosterone and Bone Health in Men

Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocrine Reviews. 2008;29(4):441–464.

Orwoll ES et al. Testosterone and fracture risk in older men. Journal of Clinical Endocrinology & Metabolism. 2014;99(9):316–325.

Testosterone, Progesterone, and Bone Health in Women

Prior JC. Progesterone for the prevention and treatment of osteoporosis in women. Climacteric. 2018;21(4):366–374.

Prior JC. Perimenopause: The complex endocrinology of the menopausal transition. Endocrine Reviews. 1998;19(4):397–428.

Prior JC, Hitchcock CL. Progesterone, not estrogen, is the dominant bone-forming hormone in women. Journal of Obstetrics and Gynaecology Canada. 2012;34(2):116–121.

Androgens (Including Testosterone) in Women

Davis SR, Wahlin-Jacobsen S. Testosterone in women—clinical significance. Lancet Diabetes & Endocrinology. 2015;3(12):980–992.

Fogle RH et al. Androgen deficiency in women: Diagnostic and therapeutic implications. Fertility and Sterility. 2007;88(6):1542–1551.

DHEA and Skeletal Health (Women and Men)

Nair KS et al. DHEA in elderly women and men: Effects on bone density and body composition. New England Journal of Medicine. 2006;355:1647–1659.

Weiss EP et al. DHEA replacement therapy in older adults. American Journal of Clinical Nutrition. 2009;89(5):1459–1467.

Bone remodeling is hormonally regulated in both women and men. While testosterone decline is often emphasized in men, relative androgen deficiency and progesterone loss in women significantly contribute to bone fragility and fracture risk and must be evaluated independently.

Magnesium & Bone Remodeling

Rude RK et al. Magnesium deficiency and bone disease. Journal of Bone and Mineral Research. 2009;24:101–106.

Castiglioni S et al. Magnesium and osteoporosis. Nutrients. 2013;5:3022–3033.

Nielsen FH. Magnesium deficiency and bone health. Magnesium Research. 2010;23:1–8.

Vitamin D: Functional Targets, Dosing & Outcomes

Holick MF. Vitamin D deficiency. New England Journal of Medicine. 2007;357:266–281.

Heaney RP et al. Vitamin D dose–response relationships. Journal of Steroid Biochemistry & Molecular Biology. 2011;121:136–138.

Bischoff-Ferrari HA et al. Vitamin D dosing and fracture prevention. BMJ. 2016;353:i2865.

GrassrootsHealth

GrassrootsHealth Nutrient Research Institute. Vitamin D Action and population-based outcome data.

– Large-scale observational and interventional data correlating serum 25(OH)D levels (40–80 ng/mL) with improved skeletal, immune, and cardiometabolic outcomes.

Vitamin D Council

Vitamin D Council Clinical Guidelines and Research Summaries.

– Evidence-based educational resources on vitamin D physiology, dosing frameworks, and target serum levels informed by peer-reviewed research.

(GrassrootsHealth and Vitamin D Council resources are widely cited in clinical integrative and functional medicine literature and are used to complement peer-reviewed journal data.)

Vitamin K2 (MK-7)

Knapen MHJ et al. Vitamin K2 supplementation improves bone strength. Osteoporosis International. 2013;24:2499–2507.

Rheaume-Bleue K. Vitamin K2 and the Calcium Paradox. Wiley; 2012.

Collagen, Protein & Bone Matrix

Sahni S et al. Protein intake and bone health. American Journal of Clinical Nutrition. 2009;89:196–203.

König D et al. Collagen supplementation and musculoskeletal health. Nutrients. 2018;10:1802.

Strontium & Bone Material Properties

Meunier PJ et al. Strontium and vertebral fracture risk. New England Journal of Medicine. 2004;350:459–468.

Blake GM et al. Effects of strontium on bone density interpretation. Bone. 2007;40:117–125.

Nielsen SP. Strontium and bone strength. Osteoporosis International. 2004;15:465–473.

Mechanical Loading & Exercise

Turner CH. Three rules for bone adaptation. Bone. 1998;23:399–407.

Daly RM et al. Exercise and bone strength. Journal of Bone and Mineral Research. 2014;29:221–229.

Cannabidiol (CBD) & Bone Remodeling

Kogan NM et al. Cannabidiol enhances fracture healing. Journal of Bone and Mineral Research. 2015;30:1905–1913.